A unit of Rostec, Russia's state corporation, has inked a pact with the Serum Institute of India to locally produce several vaccines in Russia, the Pharma Letter reports, a development that could bring about "significant losses" for Pfizer and GlaxoSmithKline in the country.
Takeda wants to join the likes of India's Hilleman Labs and Serum Institute and grab a piece of the low-cost vaccine pie. The Japanese pharma closed a €3 million ($3.3 million) equity investment in Belgium-based Univercell to use the latter's technology with vaccines in Takeda's pipeline to produce affordable vaccines for developing countries.
Building on an existing relationship, Indian generics giant Cipla and vaccines outfit Serum Institute of India on Thursday announced a collaboration to bring Serum's vaccines to South Africa.
Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.
Serum Institute of India and compatriot Cipla have inked a pact to market a flu vaccine.
In December, Serum Institute of India reported victory in a Phase I trial of its powdered measles vaccine. But it may have to go back to the drawing board as results from a noninferiority trial reported Thursday showed that the powdered candidate was not as effective as the traditional injected vaccine.
Swine flu is making a comeback in India, and with a vengeance. After destroying their existing stocks due to poor demand and short shelf life, Serum Institute and Bharat Biotech will be racing to get their swine flu vaccines back on the market.
Serum Institute of India and Cipla already have an agreement to distribute the former's low-cost vaccines in Europe, but the partnership may not stop there. The two India-based companies have held preliminary discussions on a possible merger, said Cyrus Poonawalla, chairman of Serum Institute.
With recent news of clinical trials for its low-cost HPV vaccine, the Serum Institute has already made waves in the world of Big Pharma. The India-based vaccinemaker is now gearing up to challenge the world's leading vaccinemakers in another area: pertussis.
Serum Institute of India, which has a history of undercutting its competition in the vaccine sphere, is expanding this undercutting game to HPV. Its low-cost competitor to Merck's Gardasil could hit the market in late 2018 at one-third the price.